Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 339-342

  Lin, Xiran ^a   Tian, Huang ^a   Xianmin, Meng ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CELL ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INHERITANCE; LYMPHOCYTE SUBPOPULATION; MELANOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VITILIGO;

AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS; MELANOCYTES; MODELS, IMMUNOLOGICAL; SELF TOLERANCE; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS; VITILIGO;

EID: 79751536136     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.10.034     Document Type: Article

References (45)

1. Halder R.M., Chappell J.L. Vitiligo update. Semin Cutan Med Surg 2009, 28:86-92.
2. Kent G., Al'Abadie M.S.K. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996, 35:895-898.
3. Falabella R., Barona M.I. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res 2009, 22:42-65.
4. Taeb A., Picardo M. Clinical practice Vitiligo. N Engl J Med 2009, 360:160-169.
5. Boissy R.E., Spritz R.A. Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff. Exp Dermatol 2009, 18:583-585.
6. Schneider P., MacKay F., Steiner V., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
7. Krivosikova M., Dallos T., Maslinski W., Buc M. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases. Bratisl Lek Listy 2009, 110:137-145.
8. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
9. Yanaba K., Bouaziz J.D., Matsushita T., et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008, 223:284-299.
10. Mackay F., Cancro M.P. Travelling with the BAFF/BLyS family: are we there yet?. Semin Immunol 2006, 18:261-262.
11. Huard B., Schneider P., Mauri D., Tschopp J., French L.E. T cell costimulation by the TNF ligand BAFF. J Immunol 2001, 167:6225-6231.
12. Naughton G.K., Eisinger M., Bystryn J.C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983 Dec, 81:540-542.
13. Yu H.S., Kao C.H., Yu C.L. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993, 100:823-828.
14. Naughton G.K., Reggiardo D., Bystryn J.C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986, 15:978-981.
15. Harning R., Cui J., Bystryn J.C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991, 97:1078-1080.
16. Norris D.A., Kissinger R.M., Naughton G.M., Bystryn J.C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988, 90:783-789.
17. Gilhar A., Zelickson B., Ulman Y., Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995, 105:683-686.
18. Ruiz-Argüelles A., Brito G.J., Reyes-Izquierdo P., Pérez-Romano B., Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 2007, 29:281-286.
19. Ogg G.S., Rod Dunbar P., Romero P., Chen J.L., Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998, 188:1203-1208.
20. Palermo B., Campanelli R., Garbelli S., et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001, 117:326-332.
21. Lang K.S., Caroli C.C., Muhm A., et al. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001, 116:891-897.
22. Badri A.M., Todd P.M., Garioch J.J., Gudgeon J.E., Stewart D.G., Goudie R.B. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993, 170:149-155.
23. van den Wijngaard R., Wankowicz-Kalinska A., Le Poole C., Tigges B., Westerhof W., Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000, 80:1299-1309.
24. van den Boorn J.G., Konijnenberg D., Dellemijn T.A., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
25. Rezaei N., Gavalas N.G., Weetman A.P., Kemp E.H. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007, 21:865-876.
26. Hann S.K., Park Y.K., Chung K.Y., Kim H.I., Im S., Won J.H. Peripheral blood lymphocyte imbalance in Koreans with active vitiligo. Int J Dermatol 1993, 32:286-289.
27. Salmasi J.M., Kharitonova N.I., Kazimirsky A.N., Semenova L.Y., Poryadin G.V., Volnukhin V.A. Characterization of lymphocyte surface markers in patients with vitiligo. Russ J Immunol 2003, 8:47-52.
28. Bouaziz J.D., Yanaba K., Venturi G.M., et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007, 104:20882-20887.
29. Palmer M.T., Weaver C.T. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 2010, 11:36-40.
30. Yang M., Hase H., Legarda-Addison D., Varughese L., Seed B., Ting A.T. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 2005, 175:2814-2824.
31. Sutherland A.P., Ng L.G., Fletcher C.A., et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005, 174:5537-5544.
32. Bouaziz J.D., Yanaba K., Venturi G.M., et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007, 104:20878-20883.
33. Correia O., Delgado L., Roujeau J.C., Le Cleach L., Fleming-Torrinha J.A. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002, 138:29-32.
34. Honda Y., Okubo Y., Koga M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol 1997, 24:561-563.
35. Yeo U.C., Yang Y.S., Park K.B., et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999, 19:182-188.
36. Caixia T., Hongwen F., Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999, 21:59-62.
37. Zailaie M.Z. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. Saudi Med J 2005, 26:1085-1091.
38. Kurts C., Heath W.R., Carbone F.R., Kosaka H., Miller J.F. Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity. Novartis Found Symp 1998, 215:172-181.
39. Lee J., Dollins C.M., Boczkowski D., Sullenger B.A., Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 2008, 125:229-240.
40. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010, 184:4006-4016.
41. Mariño E., Grey S.T. A new role for an old player: do B cells unleash the self-reactive CD8+ T cell storm necessary for the development of type 1 diabetes?. J Autoimmun 2008, 31:301-305.
42. Suzuki E., Kobayashi Y., Kawano O., et al. Expression of AIRE in thymocytes and peripheral lymphocytes. Autoimmunity 2008, 41:133-139.
43. Lindh E., Lind S.M., Lindmark E., et al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci USA 2008, 105:18466-18471.
44. Tazi-Ahnini R., McDonagh A.J., Wengraf D.A., et al. The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. Br J Dermatol 2008, 159:591-596.
45. Ryan M.C., Grewal I.S. Targeting of BAFF and APRIL for autoimmunity and oncology. Adv Exp Med Biol 2009, 647:52-63.